Advanced Endometrial Cancer: Treatment Optimization : Episode 16

Discussing Dose Reductions and Interruptions with Patients on Therapy for Endometrial Cancer

January 20, 2023

By Courtney R. Arn, APRN-CNP
Kimberly Halla, NP

Commentary

Video

Kimberly A. Spickes, CNP, discusses how often patients with endometrial cancer have dose reductions or interruptions at her institution, and who is involved in the decision to dose-reduce.

EP: 1.Symptoms and Diagnosis of Endometrial Cancer

EP: 2.Initial Consultation of Patients With Advanced Endometrial Cancer

EP: 3.Conversations with Patients With Advanced Endometrial Cancer Before and After Diagnosis

EP: 4.Resources for Patients With Endometrial Cancer

EP: 5.Patient Profile Presentation: A 76-Year-Old Woman With Advanced Endometrial Cancer

EP: 6.Fertility and Other Treatment Considerations for Patients With Advanced Endometrial Cancer

EP: 7.Currently Available Treatment Modalities in Endometrial Cancer

EP: 8.First-Line Treatments for Patients With Advanced Endometrial Cancer Who Are Unfit for Surgery

EP: 9.Common Adverse Events Seen With Chemotherapy for Advanced Endometrial Cancer

EP: 10.Efficacy of Chemotherapy in Patients with Advanced Endometrial Cancer

EP: 11.Treatment Options for Patients with Recurrent Endometrial Cancer

EP: 12.Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events

EP: 13.Monitoring Patients on Therapy for Recurrent Endometrial Cancer

EP: 14.Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

EP: 15.Proactive Adverse Effect Management for Patients on Therapy for Endometrial Cancer

Now Viewing

EP: 16.Discussing Dose Reductions and Interruptions with Patients on Therapy for Endometrial Cancer

EP: 17.Greatest Unmet Needs for Patients with Endometrial Cancer

EP: 18.Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!

Latest Conference Coverage

Nurses, APPs Key to AE Management as T-Cell Engagers Move Into Solid Tumors

PI3K and AKT Inhibitor Toxicity Advice From a Breast Cancer Expert

Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777